Dual Neonate Vaccine Platform Against HIV-1 and M. Tuberculosis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 May 24

PMID 21603645

Citations 19

Authors

Richard Hopkins

Anne Bridgeman

Joan Joseph

Sarah C Gilbert

Helen McShane

Tomas Hanke

Affiliations

Soon will be listed here.

Abstract

Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world's most devastating diseases. The first vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Guérin (BCG) as a prevention against TB. BCG protects against disseminated disease in the first 10 years of life, but provides a variable protection against pulmonary TB and enhancing boost delivered by recombinant modified vaccinia virus Ankara (rMVA) expressing antigen 85A (Ag85A) of M. tuberculosis is currently in phase IIb evaluation in African neonates. If the newborn's mother is positive for human immunodeficiency virus type 1 (HIV-1), the baby is at high risk of acquiring HIV-1 through breastfeeding. We suggested that a vaccination consisting of recombinant BCG expressing HIV-1 immunogen administered at birth followed by a boost with rMVA sharing the same immunogen could serve as a strategy for prevention of mother-to-child transmission of HIV-1 and rMVA expressing an African HIV-1-derived immunogen HIVA is currently in phase I trials in African neonates. Here, we aim to develop a dual neonate vaccine platform against HIV-1 and TB consisting of BCG.HIVA administered at birth followed by a boost with MVA.HIVA.85A. Thus, mMVA.HIVA.85A and sMVA.HIVA.85A vaccines were constructed, in which the transgene transcription is driven by either modified H5 or short synthetic promoters, respectively, and tested for immunogenicity alone and in combination with BCG.HIVA(222). mMVA.HIVA.85A was produced markerless and thus suitable for clinical manufacture. While sMVA.HIVA.85A expressed higher levels of the immunogens, it was less immunogenic than mMVA.HIVA.85A in BALB/c mice. A BCG.HIVA(222)-mMVA.HIVA.85A prime-boost regimen induced robust T cell responses to both HIV-1 and M. tuberculosis. Therefore, proof-of-principle for a dual anti-HIV-1/M. tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life.

Citing Articles

Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.

Kaur A, Vaccari M Viruses. 2024; 16(3).

PMID: 38543734 PMC: 10974975. DOI: 10.3390/v16030368.

BCG immunomodulation: From the 'hygiene hypothesis' to COVID-19.

Moulson A, Av-Gay Y Immunobiology. 2021; 226(1):152052.

PMID: 33418320 PMC: 7833102. DOI: 10.1016/j.imbio.2020.152052.

Vaccine strategies for the /HIV copandemic.

Sharan R, Kaushal D NPJ Vaccines. 2020; 5:95.

PMID: 33083030 PMC: 7555484. DOI: 10.1038/s41541-020-00245-9.

BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.

Covian C, Fernandez-Fierro A, Retamal-Diaz A, Diaz F, Vasquez A, Lay M Front Immunol. 2019; 10:2806.

PMID: 31849980 PMC: 6896902. DOI: 10.3389/fimmu.2019.02806.

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpelainen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C Vaccines (Basel). 2019; 7(3).

PMID: 31382453 PMC: 6789536. DOI: 10.3390/vaccines7030078.

References

Webb T, Litavecz R, Khan M, Du W, Gervay-Hague J, Renukaradhya G . Inhibition of CD1d1-mediated antigen presentation by the vaccinia virus B1R and H5R molecules. Eur J Immunol. 2006; 36(10):2595-600. DOI: 10.1002/eji.200636024. View

Im E, Hanke T . MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines. 2004; 3(4 Suppl):S89-97. DOI: 10.1586/14760584.3.4.s89. View

Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B . Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med. 1988; 168(4):1211-24. PMC: 2189091. DOI: 10.1084/jem.168.4.1211. View

Nkolola J, Wee E, Im E, Jewell C, Chen N, Xu X . Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. 2004; 11(13):1068-80. DOI: 10.1038/sj.gt.3302241. View

Earl P, Cotter C, Moss B, VanCott T, Currier J, Eller L . Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 2009; 27(42):5885-95. PMC: 2743792. DOI: 10.1016/j.vaccine.2009.07.039. View

Stover C, de la Cruz V, Fuerst T, Burlein J, Benson L, Bennett L . New use of BCG for recombinant vaccines. Nature. 1991; 351(6326):456-60. DOI: 10.1038/351456a0. View

Chege G, Thomas R, Shephard E, Meyers A, Bourn W, Williamson C . A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons. Vaccine. 2009; 27(35):4857-66. DOI: 10.1016/j.vaccine.2009.05.064. View

McShane H, Brookes R, Gilbert S, Hill A . Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun. 2001; 69(2):681-6. PMC: 97939. DOI: 10.1128/IAI.69.2.681-686.2001. View

Scriba T, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F . Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2009; 40(1):279-90. PMC: 3044835. DOI: 10.1002/eji.200939754. View

10.

Smith C, Dunbar P, Mirza F, Palmowski M, Shepherd D, Gilbert S . Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer. 2004; 113(2):259-66. DOI: 10.1002/ijc.20569. View

11.

Verreck F, Vervenne R, Kondova I, van Kralingen K, Remarque E, Braskamp G . MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One. 2009; 4(4):e5264. PMC: 2666807. DOI: 10.1371/journal.pone.0005264. View

12.

Liu L, Chavan R, Feinberg M . Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008; 9:15. PMC: 2359732. DOI: 10.1186/1471-2172-9-15. View

13.

Joseph J, Fernandez-Lloris R, Pezzat E, Saubi N, Cardona P, Mothe B . Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors. J Biomed Biotechnol. 2010; 2010:357370. PMC: 2896670. DOI: 10.1155/2010/357370. View

14.

Cayabyab M, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A . Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol. 2009; 83(11):5505-13. PMC: 2681969. DOI: 10.1128/JVI.02544-08. View

15.

Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, Dasgupta A . Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine. 2009; 28(6):1547-57. PMC: 2821965. DOI: 10.1016/j.vaccine.2009.11.056. View

16.

McShane H, Hill A . Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 2005; 7(5-6):962-7. DOI: 10.1016/j.micinf.2005.03.009. View

17.

Rodrigues L, Diwan V, Wheeler J . Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol. 1993; 22(6):1154-8. DOI: 10.1093/ije/22.6.1154. View

18.

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

19.

Hesseling A, Cotton M, von Reyn C, Graham S, Gie R, Hussey G . Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008; 12(12):1376-9. View

20.

Li P, Wang N, Zhou D, Yee C, Chang C, Brutkiewicz R . Disruption of MHC class II-restricted antigen presentation by vaccinia virus. J Immunol. 2005; 175(10):6481-8. DOI: 10.4049/jimmunol.175.10.6481. View